abs73.txt	background		differential	use	of	endocrine	therapy	(et)	by	race	may	contribute	tobreast	cancer	outcome	disparities	but	racial	differences	in	et	behaviors	arepoorly	understood	methods	women	aged	20-74	years	with	a	first	primary	stage	i-iii	hormonereceptor-positive	(hr+)	breast	were	included	at	2	postdiagnosis	weassessed	nonadherence	defined	as	not	taking	every	day	or	missing	more	thantwo	pills	the	past	14	days	discontinuation	and	composite	measure	ofunderuse	either	discontinuing	completely	usinglogistic	regression	we	evaluated	relationship	between	overall	underuse	unadjusted	clinically	adjusted	andsocioeconomically	models	results	total	1280	43	2%	self-identified	black	compared	to	white	often	reported	(13	7%	vs5	2%)	(10	0%	vs	10	7%)	also	oftenreported	following	hot	flashes	night	sweats	sensitivity	jointpain	believing	that	their	recurrence	risk	would	change	if	they	stopped	forgetting	take	cost-related	barriers	multivariable	analysis	remained	statistically	significantly	associated	nonadherenceafter	adjusting	for	clinical	characteristics	(adjusted	odds	ratio	=	72	95%confidence	interval	1	75	4	24)	after	adding	socioeconomic	clinicalcharacteristics	44	95%	confidence	50	to3	97)	was	independently	adjustment	low	perception	lack	shared	decision	making	stronglypredictive	across	races	conclusions	our	highlight	important	et-adherencebehaviors	perceptions	benefits/harms	betargeted	culturally	tailored	interventions
